Breast Cancer

Data from the APHINITY trial suggested that patients with early breast cancer with a HER2 single-activated pathway determined by molecular subtyping using BluePrint assay demonstrated a trend for greater benefit with adjuvant pertuzumab (Perjeta) therapy.

Treatment with the combination of oral paclitaxel and encequidar was found to be associated with greater efficacy in patients with metastatic breast cancer, as well as lower rates of chemotherapy-induced peripheral neuropathy, compared to intravenous paclitaxel.

Behavioral interventions were found to help young breast cancer survivors in reducing their depressive symptoms.

Ribociclib plus endocrine therapy continued to show a significant overall survival improvement, while delaying subsequent chemotherapy for patients with HR+/HER2-negative breast cancer.

An analysis of tamoxifen versus anastrozole showed no significant difference in terms of disease recurrence in postmenopausal women with locally excised ductal carcinoma in situ; however, the findings may highlight the understanding of associated toxicities.

PreciseDx, an artificial intelligence–digital breast cancer risk discrimination platform, was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain images and limited clinical data.

After breast-conserving surgery and adjuvant endocrine therapy, whole breast irradiation can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years.

A retrospective exploratory analysis found that intrinsic tumor subtype was associated with prognosis in patients with hormone receptor–positive, HER2-negative advanced breast cancer who received the CDK4/6 inhibitor ribociclib.

Treatment with oral paclitaxel, compared with the intravenous formulation, in combination with encequidar led to an estimated 26.5% reduction in the risk of death in patients with metastatic breast cancer, according to updated phase 3 findings of the KX-ORAX-001 trial.

A poster presented at the 2020 San Antonio Breast Cancer Symposium found a trend towards less frequent care refusal when a safety net hospital introduced nurse breast navigators.

Study results suggested that while chemotherapy-induced nausea/vomiting (CINV) can be treated, there is potential for it to return, especially for patients for whom CINV treatment did not work the first time around.

Research presented at the 2020 San Antonio Breast Cancer Symposium highlighted the need for reliable information to address the educational and psychosocial needs of patients with newly diagnosed metastatic breast cancer.

Chemotherapy plus endocrine therapy improved 5-year invasive disease-free and overall survival in premenopausal women with HR–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.

The use of serial circulating tumor cell enumeration was confirmed to strongly predict overall survival outcomes in patients with metastatic breast cancer.

Women who were younger, diagnosed with breast cancer, and received chemotherapy were reported to have a higher risk of new chronic controlled substance use following mastectomy with reconstruction.

The study found that 53.2% of patients who reported at least 1 substantial symptom while receiving radiotherapy experienced under-recognition of at least 1 of 4 symptoms by their physician.

Treatment with abemaciclib and standard endocrine therapy reduced the risk of invasive disease recurrence or death in patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

This study found that abbreviated breast magnetic resonance imaging as a supplemental screening test in women with dense breasts shows an increase in cancer detection over digital breast tomosynthesis screening.

Low EC-pY397-FAK expression levels were found to be associated with chemotherapy sensitivity and improved 5-year relapse-free survival after systemic therapy in patients with neoadjuvant-treated locally advanced breast cancer.

Women with onset of breast cancer over age 65 typically do not qualify for genetic testing, however this study demonstrated that frequency of pathogenic variants and risk of breast cancer is not negligible in this patient population.

“In the current era of effective multimodality therapy for breast cancer, the need for [axillary lymph node dissection] for patients with axillary lymph node metastases must be re-evaluated, even for patients with clinically positive nodal disease,” the study authors wrote.

The FDA approved the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with triple-negative breast cancer who may be appropriate for treatment with pembrolizumab (Keytruda).

The FDA granted accelerated approval to pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1 as determined by an FDA approved test.

Researchers indicated that there is still a persistent survival disparity that has not narrowed over 2 decades between white and Black patients with inflammatory breast cancer.

A recent study found that automated analyses of CT scans for patients with breast cancer can predict which patients are likely to develop cardiovascular disease in the future.

A study presented at the 12th European Breast Cancer Conference suggests women over the age of 70 with breast cancer can tolerate surgery even though they aren’t offered it regularly, but a second abstract suggests these women tend to opt out of this treatment option.

A study revealed that the way data is collected regarding women with benign breast diseases can provide insight into which non-cancerous disorders are likely to become cancerous in the future.

A study led by Jefferson researchers found that not all patients, specifically African American patients and women without private insurance, receive the same breast cancer treatment, specifically the beneficial and more cost-effective hypofractionated whole breast radiation therapy.

According to researchers, these findings “support the hypothesis that regional nodal disease may precede and contribute to the seeding of distant foci.”

Detection of ESR1 mutations in baseline ctDNA was associated with inferior progression-free survival and overall survival in patients with advanced HR-positive breast cancer treated with exemestane versus fulvestrant.